Alliancebernstein L.P. Has $25.28 Million Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Alliancebernstein L.P. boosted its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 13.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,159,776 shares of the company’s stock after acquiring an additional 136,633 shares during the quarter. Alliancebernstein L.P. owned 3.92% of Dianthus Therapeutics worth $25,283,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of DNTH. R Squared Ltd purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $26,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Dianthus Therapeutics during the 4th quarter worth about $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at about $35,000. AlphaQuest LLC lifted its holdings in shares of Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock valued at $91,000 after buying an additional 3,072 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at approximately $201,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on DNTH shares. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen started coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. Guggenheim reaffirmed a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush reissued an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $54.33.

Dianthus Therapeutics Price Performance

DNTH stock opened at $15.61 on Tuesday. The stock has a market capitalization of $501.47 million, a price-to-earnings ratio of -6.24 and a beta of 1.62. The company has a 50-day moving average of $21.37 and a two-hundred day moving average of $23.81. Dianthus Therapeutics, Inc. has a 52-week low of $14.78 and a 52-week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. The firm had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Equities analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.